Hormonal
Ipamorelin
Selective Growth Hormone Secretagogue
Scientific Overview
Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist developed as a growth-hormone secretagogue with reduced ACTH/cortisol off-target activity relative to earlier GHRPs.
Mechanism focus: Binds GHS-R1a to stimulate pituitary GH release in a pulse-compatible manner; studied for nitrogen balance, bone, and GI motility endpoints in animals.
Research Use Cases
- Selective GH secretagogue pharmacology
- Postoperative ileus rodent models
- Bone mineral / longitudinal growth studies
- GH axis biomarker panels
Use-Case Study Notations
- Case-study notation: foundational papers describe ipamorelin as the first highly selective GH secretagogue.
- Case-study notation: rodent postoperative ileus work evaluated ghrelin-mimetic motility effects.
- Differentiate research peptide lots from pharmaceutical secretagogue development compounds.
Selected Studies (English, PubMed)
Five peer-reviewed sources indexed on PubMed. Links open the PubMed record for verification.
- Ipamorelin, the first selective growth hormone secretagogue — PubMed 9849822
- Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus — PubMed 19289567
- The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult rats — PubMed 10828840
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats — PubMed 10373343
- Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis — PubMed 19231263
Related compounds
Research Use Only. This page is educational and intended for laboratory research context. Products are not for human consumption and are not intended to diagnose, treat, cure, or prevent any disease.